Literature DB >> 22884669

Elevated serum levels of high mobility group box 1 (HMGB1) protein in dengue-infected patients are associated with disease symptoms and secondary infection.

Diego Allonso1, Fabricio S Belgrano, Naifi Calzada, Maria G Guzmán, Susana Vázquez, Ronaldo Mohana-Borges.   

Abstract

BACKGROUND: Dengue virus (DENV) is described as the most prevalent arbovirus, infecting at least 50 million people worldwide. During infection, an intricate network of cytokines, a group of substances closely related to disease severity, is released. Recently, it was observed that both DENV-infected epithelial cells undergoing necrosis and dendritic cells (DCs) are able to release a non-classical pro-inflammatory cytokine called high mobility group box 1 (HMGB1).
OBJECTIVES: The aim of this study was to evaluate whether HMGB1 levels were altered in DENV-infected patients' sera and whether this augment correlated with disease pathogenesis. STUDY
DESIGN: Samples from DENV-infected patients were collected from different days after the onset of symptoms and from patients experiencing primary or secondary infection. The circulating HMGB1 concentration was measured in healthy blood donors as well as in donors with primary and secondary cases of DENV infection by a quantitative capture ELISA assay.
RESULTS: We observed that the HMGB1 concentration in DENV-infected patients was significantly higher than in healthy patients. HMGB1 levels reached the highest concentration in the first day after the onset of symptoms and decreased throughout the course of the infection. Moreover, we observed that the HMGB1 concentration was augmented during secondary infection as well.
CONCLUSION: We hypothesize that HMGB1 levels correlate with disease pathogenesis, specifically with the clinical symptoms and secondary infection, implicating a pro-inflammatory cytokine role for HMGB1 in DENV infection. This is the first report assessing the circulating levels of HMGB1 during DENV infection.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884669     DOI: 10.1016/j.jcv.2012.07.010

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  18 in total

1.  High-mobility group box-1 and receptor for advanced glycation end products in preterm infants with brain injury.

Authors:  Hong-Yan Lu; Jiang-Lin Ma; Ji-Yan Shan; Jie Zhang; Qiu-Xia Wang; Qiang Zhang
Journal:  World J Pediatr       Date:  2016-12-20       Impact factor: 2.764

Review 2.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

3.  High mobility group box 1 protein as an auxiliary biomarker for dengue diagnosis.

Authors:  Diego Allonso; Susana Vázquez; Maria G Guzmán; Ronaldo Mohana-Borges
Journal:  Am J Trop Med Hyg       Date:  2012-12-26       Impact factor: 2.345

4.  High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4.

Authors:  Eileen M Bauer; Richard Shapiro; Han Zheng; Ferhaan Ahmad; David Ishizawar; Suzy A Comhair; Serpil C Erzurum; Timothy R Billiar; Philip M Bauer
Journal:  Mol Med       Date:  2013-02-08       Impact factor: 6.354

5.  Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice.

Authors:  Nobuyuki Nosaka; Masato Yashiro; Mutsuko Yamada; Yosuke Fujii; Hirokazu Tsukahara; Keyue Liu; Masahiro Nishibori; Akihiro Matsukawa; Tsuneo Morishima
Journal:  Crit Care       Date:  2015-06-11       Impact factor: 9.097

6.  Role of the acidic tail of high mobility group protein B1 (HMGB1) in protein stability and DNA bending.

Authors:  Fabricio S Belgrano; Isabel C de Abreu da Silva; Francisco M Bastos de Oliveira; Marcelo R Fantappié; Ronaldo Mohana-Borges
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

7.  Assessing positivity and circulating levels of NS1 in samples from a 2012 dengue outbreak in Rio de Janeiro, Brazil.

Authors:  Diego Allonso; Marcelo D F Meneses; Carlos A Fernandes; Davis F Ferreira; Ronaldo Mohana-Borges
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

8.  Mapping the interactions of dengue virus NS1 protein with human liver proteins using a yeast two-hybrid system: identification of C1q as an interacting partner.

Authors:  Emiliana M Silva; Jonas N Conde; Diego Allonso; Mauricio L Nogueira; Ronaldo Mohana-Borges
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

9.  Altered protein networks and cellular pathways in severe west nile disease in mice.

Authors:  Christophe Fraisier; Luc Camoin; Stephanie M Lim; Stéphanie Lim; Mahfoud Bakli; Maya Belghazi; Patrick Fourquet; Samuel Granjeaud; Ab D M E Osterhaus; Penelope Koraka; Byron Martina; Lionel Almeras
Journal:  PLoS One       Date:  2013-07-10       Impact factor: 3.240

10.  Transcriptomic profiling of diverse Aedes aegypti strains reveals increased basal-level immune activation in dengue virus-refractory populations and identifies novel virus-vector molecular interactions.

Authors:  Shuzhen Sim; Natapong Jupatanakul; José L Ramirez; Seokyoung Kang; Claudia M Romero-Vivas; Hamish Mohammed; George Dimopoulos
Journal:  PLoS Negl Trop Dis       Date:  2013-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.